Difficulties and pitfalls in the laboratory diagnosis of bleeding disorders

Haemophilia

Volumn 18, Issue SUPPL.4, 2012, Pages 66-72

  Bolton Maggs, P H B ^a   Favaloro, E J ^b   Hillarp, A ^c   Jennings, I ^d   Kohler, H P ^e,f  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b WESTMEAD HOSPITAL   (Australia)

^c Lund University   (Sweden)

^d UK NEQAS for Blood Coagulation   (United Kingdom)

^e UNIVERSITY OF BERN   (Switzerland)

^f Spital Netz Bern   (Switzerland)

Author keywords

Bleeding disorders; External quality assurance; Factor XIII deficiency; Laboratory diagnosis; Von Willebrand disease

Indexed keywords

BLOOD CLOTTING FACTOR 8; FIBRINOGEN; RECOMBINANT BLOOD CLOTTING FACTOR 8; VON WILLEBRAND FACTOR;

AGE DISTRIBUTION; ARTICLE; BLEEDING DISORDER; BLOOD GROUP ABO SYSTEM; CLINICAL FEATURE; COMPLEMENT HEMOLYSIS TEST; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE MUTATION; HEMOPHILIA A; HEMOSTASIS; HUMAN; INFECTION; LABORATORY DIAGNOSIS; PATIENT ASSESSMENT; PREGNANCY; PRIORITY JOURNAL; QUALITY CONTROL; STRESS; VON WILLEBRAND DISEASE;

CLINICAL LABORATORY TECHNIQUES; COLLAGEN; FACTOR XIII DEFICIENCY; HEMAGGLUTININS; HEMOPHILIA A; HUMANS; PLATELET AGGREGATION; QUALITY CONTROL; RISTOCETIN; VON WILLEBRAND DISEASES; VON WILLEBRAND FACTOR;

EID: 84862883345     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2012.02830.x     Document Type: Article

References (43)

1. Favaloro EJ. von Willebrand disease: local diagnosis and management of a globally distributed bleeding disorder. Semin Thromb Hemost 2011; 37: 440-55.
2. Howard MA, Firkin BG. Ristocetin--a new tool in the investigation of platelet aggregation. Thromb Diath Haemorrh 1971; 26: 362-9.
3. Weiss HJ, Rogers J, Brand H. Defective ristocetin-induced platelet aggregation in von Willebrand's disease and its correction by factor VIII. J Clin Invest 1973; 52: 2697-707.
4. Macfarlane DE, Stibbe J, Kirby EP et al. Letter: a method for assaying von Willebrand factor (ristocetin cofactor). Thromb Diath Haemorrh 1975; 34: 306-8.
5. Sadler JE, Budde U, Eikenboom JC et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 2006; 4: 2103-14.
6. Favaloro EJ, Bonar R, Marsden K. Lower limit of assay sensitivity: an under-recognised and significant problem in von Willebrand disease identification and classification. Clin Lab Sci 2008; 21: 178-83.
7. Favaloro EJ, Bonar R, Meiring M, Street A, Marsden K. 2B or not 2B? Disparate discrimination of functional VWF discordance using different assay panels or methodologies may lead to success or failure in the early identification of type 2B VWD. Thromb Haemost 2007; 98: 346-58.
8. Favaloro EJ, Mohammed S, McDonald J. Validation of improved performance characteristics for the automated von Willebrand factor ristocetin cofactor activity assay. J Thromb Haemost 2010; 8: 2842-4.
9. Hillarp A, Stadler M, Haderer C, Weinberger J, Kessler CM, Romisch J. Improved performance characteristics of the von Willebrand factor ristocetin cofactor activity assay using a novel automated assay protocol. J Thromb Haemost 2010; 8: 2216-23.
10. Favaloro EJ. Diagnosis and classification of von Willebrand disease: a review of the differential utility of various functional von Willebrand factor assays. Blood Coagul Fibrinolysis 2011; 22: 553-64.
11. Ruggeri ZM, Pareti FI, Mannucci PM, Ciavarella N, Zimmerman TS. Heightened interaction between platelets and factor VIII/von Willebrand factor in a new subtype of von Willebrand's disease. N Engl J Med 1980; 302: 1047-51.
12. Favaloro EJ. Phenotypic identification of platelet-type von Willebrand disease and its discrimination from type 2B von Willebrand disease: a question of 2B or not 2B? A story of nonidentical twins? Or two sides of a multidenominational or multifaceted primary-hemostasis coin? Semin Thromb Hemost 2008; 34: 113-27.
13. Murdock PJ, Woodhams BJ, Matthews KB, Pasi KJ, Goodall AH. von Willebrand factor activity detected in a monoclonal antibody-based ELISA: an alternative to the ristocetin cofactor platelet agglutination assay for diagnostic use Thromb Haemost 1997; 78: 1272-7.
14. Chen D, Tange JI, Meyers BJ, Pruthi RK, Nichols WL, Heit JA. Validation of an automated latex particle-enhanced immunoturbidimetric von Willebrand factor activity assay. J Thromb Haemost 2011; 9:1993-2002.
15. Flood VH, Gill JC, Morateck PA et al. Gain-of-function GPIb ELISA assay for VWF activity in the Zimmerman program for the molecular and clinical biology of VWD. Blood 2011; 117: e67-74.
16. Scneppenheim R, Obser T, Budde U, Patzke J. Development of a new functional assay for von Willebrand factor binding to platelet GP1a that does not require ristocetin. Hamostaseologie 2010; 30: FC04-5.
17. Flood VH, Friedman KD, Gill JC et al. Limitations of the ristocetin cofactor assay in measurement of von Willebrand factor function. J Thromb Haemost 2009; 7: 1832-9.
18. Patzke J, Althaus H, Obser T, Weber B, Budde U, Scneppenheim R. Evaluation of a new VWF activity assay based on GP1ba in the absence of ristocetin. Hamostaseologie 2010; 30: P07-03.
19. Patzke J, Schneppenheim R. Laboratory diagnosis of von Willebrand disease. Hamostaseologie 2010; 30: 203-6.
20. Favaloro EJ, Bonar R, Kershaw G et al. Reducing errors in identification of von Willebrand disease: the experience of the Royal College of Pathologists of Australasia quality assurance program. Semin Thromb Hemost 2006; 32: 505-13.
21. Chandler WL, Peerschke EI, Castellone DD, Meijer P. Von Willebrand factor assay proficiency testing. The North American Specialized Coagulation Laboratory Association experience. Am J Clin Pathol 2011; 135: 862-9.
22. Brown JE, Bosak JO. An ELISA test for the binding of von Willebrand antigen to collagen. Thromb Res 1986; 43: 303-11.
23. Kempfer AC, Silaf MR, Farias CE, Carballo GA, Woods AI, Lazzari MA. Binding of von Willebrand factor to collagen by flow cytometry. Am J Clin Pathol 1999; 111: 418-23.
24. Favaloro EJ. Evaluation of commercial von Willebrand factor collagen binding assays to assist the discrimination of types 1 and 2 von Willebrand disease. Thromb Haemost 2010; 104: 1009-21.
25. Favaloro EJ. Collagen binding assay for von Willebrand factor (VWF:CBA): detection of von Willebrands Disease (VWD), and discrimination of VWD subtypes, depends on collagen source. Thromb Haemost 2000; 83: 127-35.
26. Favaloro EJ. An update on the von Willebrand factor collagen binding assay: 21 years of age and beyond adolescence but not yet a mature adult. Semin Thromb Hemost 2007; 33: 727-44.
27. Jennings I, Kitchen DP, Woods TA, Kitchen S, Walker ID, Preston FE. Laboratory performance in the World Federation of Hemophilia EQA programme, 2003-2008. Haemophilia 2009; 15: 571-7.
28. Jennings I, Kitchen S, Woods TA, Preston FE. Development of the World Federation of Hemophilia Quality Assessment Scheme: results of a pilot study. Haemophilia 1996; 2: 41-6.
29. van den Besselaar AM, Haas FJ, Kuypers AW. Harmonisation of factor VIII:C assay results: study within the framework of the Dutch project 'Calibration 2000'. Br J Haematol 2006; 132: 75-9.
30. Ghosh K, Shetty S. Epidemiology, diagnosis, and management of von Willebrand disease in India. Semin Thromb Hemost 2011; 37: 595-601.
31. Nair SC, Viswabandya A, Srivastava A. Diagnosis and management of von Willebrand disease: a developing country perspective. Semin Thromb Hemost 2011; 37: 587-94.
32. Preston FE. Assays for von Willebrand factor functional activity: a UK NEQAS survey. National External Quality Assessment Scheme. Thromb Haemost 1998; 80: 863.
33. Bolton-Maggs PH, Perry DJ, Chalmers EA et al. The rare coagulation disorders--review with guidelines for management from the United Kingdom Haemophilia Centre Doctors' Organisation. Haemophilia 2004; 10: 593-628.
34. Bolton-Maggs PH, Patterson DA, Wensley RT, Tuddenham EG. Definition of the bleeding tendency in factor XI-deficient kindreds--a clinical and laboratory study. Thromb Haemost 1995; 73: 194-202.
35. Jennings I, Kitchen S, Woods TA, Preston FE. Problems relating to the laboratory diagnosis of factor XIII deficiency: a UK NEQAS study. J Thromb Haemost 2003; 1: 2603-8.
36. Muszbek L, Bereczky Z, Bagoly Z, Komaromi I, Katona E. Factor XIII: a coagulation factor with multiple plasmatic and cellular functions. Physiol Rev 2011; 91: 931-72.
37. Kaetsu H, Hashiguchi T, Foster D, Ichinose A. Expression and release of the a and b subunits for human coagulation factor XIII in baby hamster kidney (BHK) cells. J Biochem 1996; 119: 961-9.
38. Ortner E, Schroeder V, Walser R, Zerbe O, Kohler HP. Sensitive and selective detection of free FXIII activation peptide: a potential marker of acute thrombotic events. Blood 2010; 115: 5089-96.
39. Anwar R, Miloszewski KJ. Factor XIII deficiency. Br J Haematol 1999; 107: 468-84.
40. Schroeder V, Meili E, Cung T, Schmutz P, Kohler HP. Characterisation of six novel A-subunit mutations leading to congenital factor XIII deficiency and molecular analysis of the first diagnosed patient with this rare bleeding disorder. Thromb Haemost 2006; 95: 77-84.
41. Karimi M, Bereczky Z, Cohan N, Muszbek L. Factor XIII deficiency. Semin Thromb Hemost 2009; 35: 426-38.
42. Kohler HP, Ichinose A, Seitz R, Ariens RAS, Muszbek L. Diagnosis and classification of factor XIII deficiencies. J Thromb Haemost 2011; 9: 1401-6.
43. Lovejoy AE, Reynolds TC, Visich JE et al. Safety and pharmacokinetics of recombinant factor XIII-A2 administration in patients with congenital factor XIII deficiency. Blood 2006; 108: 57-62.